论文部分内容阅读
目的弱精子症作为男性不育的重要因素之一,影响着全球15%的育龄夫妇,但其发病机制尚待阐明。课题组前期研究通过基因芯片技术发现CRISP2在弱精子症患者精子中表达明显下调,但其临床意义仍有待进一步阐明。方法收集2013年1月至2013年6月的弱精子症患者及健康男性精液标本各24例,检测这些精液样本中CRISP2基因及蛋白表达水平,探讨其与精子形态、运动能力及生育预后的相关性。结果弱精子症患者精液标本中CRISP2蛋白表达水平明显低于正常对照组,而CRISP2基因mRNA表达水平并无明显统计学差异。相关性分析显示CRISP2蛋白表达水平与形态正常精子率(r=0.6182,P=0.0037)及前向运动能力(r=0.6309,P=0.0029)呈明显正相关。经过密切随访,CRISP2蛋白高表达患者配偶受孕率明显高于CRISP2蛋白低表达患者(80.0%vs 20.0%,P=0.0230)。结论 CRISP2蛋白表达水平与弱精子症患者的精子形态、前向运动能力呈正相关,且CRISP2蛋白低表达的弱精子症患者生育预后不良,提示CRISP2作为弱精子症患者治疗新靶点的潜在价值。
Objective Weak spermatozoa as one of the important factors of male infertility, affecting 15% of couples of childbearing age worldwide, but its pathogenesis remains to be elucidated. Our previous study found that CRISP2 was significantly down-regulated in sperm from patients with asthenospermia by gene chip technology, but its clinical significance remains to be elucidated. Methods Seventy-four patients with asthenospermia and healthy male semen from January 2013 to June 2013 were collected for detecting CRISP2 gene and protein expression in these semen samples, and their correlation with sperm morphology, exercise capacity and prognosis Sex. Results The expression of CRISP2 protein in seminal fluid of patients with asthenospermia was significantly lower than that of the normal control group, while the expression of CRISP2 mRNA was not significantly different. Correlation analysis showed that CRISP2 protein expression was positively correlated with morphological normal sperm rate (r = 0.6182, P = 0.0037) and forward movement ability (r = 0.6309, P = 0.0029) After close follow-up, the pregnancy rate of spouses with high CRISP2 protein expression was significantly higher than those with low CRISP2 protein expression (80.0% vs 20.0%, P = 0.0230). Conclusions The expression of CRISP2 protein is positively correlated with the sperm shape and the forward movement ability of asthenospermia patients. The poor prognosis of asthenospermia patients with low expression of CRISP2 protein suggests that CRISP2 may be a potential therapeutic target for asthenospermia patients.